Journal Guide

Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the management of cardiovascular disorders, particularly the place in therapy of newer and established agents.The journal includes current opinion on contentious issues and emerging areas, and definitive reviews on a broad range of topics relating to the optimum management of cardiovascular disorders.

An invaluable journal specifically designed as a forum for discussing, evaluating and disseminating the latest information about dermatological disorders.The American Journal of Clinical Dermatology provides healthcare practitioners with objective, peer-reviewed information covering all aspects of the management of dermatological conditions, particularly the place in therapy of newer and established agents and procedures.

Applied Health Economics and Health Policy is an international peer-reviewed journal designed to communicate the latest applied information in health economics and health policy.
Areas of interest include:  
• Economic analysis of all aspects of healthcare interventions.
• Economic analysis of health policy initiatives.
• Cost of illness studies.
• Evaluation of methodologies.
• Analysis of pricing and reimbursement systems.  

An essential resource for R&D professionals and clinicians with an interest in biologic therapies.BioDrugs covers the development and use of biotechnology-based pharmaceuticals and innovative technologies for the treatment of human disease.

Clinical Drug Investigation covers:Clinical trialsOutcomes researchPharmacoeconomics studiesPharmacoepidemiology studiesPharmacodynamic and pharmacokinetic studiesApplication of drug-delivery technology in healthcare

Clinical Pharmacokinetics is the major review journal in the area of clinical pharmacokinetics, the study of drug disposition in the human body, which is an integral part of drug development and rational use.

Drug Safety is the official journal of the International Society of Pharmacovigilance. The journal includes:   

• Overviews of contentious or emerging issues. 
• Comprehensive narrative reviews that provide an authoritative source of information on epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes. 
• In-depth benefit-risk assessment of adverse effect and efficacy data for a drug in a defined therapeutic area. 
• Systematic reviews (with or without meta-analyses) that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.
• Original research articles reporting the results of well-designed studies in disciplines such as pharmacoepidemiology, pharmacovigilance, pharmacology and toxicology, and pharmacogenomics.
• Editorials and commentaries on topical issues.

Stay up to date with the latest developments in therapeutics by reading the world’s most respected source of authoritative drug information. For over 50 years Drugs has been the definitive journal of drugs and therapeutics, promoting optimum pharmacotherapy by publishing reviews and original clinical research authored by leading international clinicians and researchers to support clinical decision-making.   

Through a rigorous and comprehensive program of peer-reviewed evaluations, Drugs provides detailed and objective analysis covering the full spectrum of new and established drug therapies in all disease areas.

As a hybrid journal, Drugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require (more information).

Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content (more information).

For 30 years Drugs & Aging has been delivering essential information on the most important aspects of drug therapy to researchers and healthcare professionals involved in the care of older patients.

Through a program of reviews and original research articles, the journal addresses major issues relating to drug therapy in older adults, including the management of specific diseases or disorders, particularly those associated with aging, age-related physiological changes impacting drug therapy, and issues related to drug utilization and prescribing.

As a hybrid journal, Drugs & Aging does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require (more information).

Drugs & Aging offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content (more information).

Drugs & Therapy Perspectives provides concise, authoritative review articles to aid drug formulary and prescribing decisions. It is a digest of the latest drug knowledge covering the most important aspects of clinical therapeutics, including:Questions and answers on the clinical use of drugs.Comparisons of the features of various drugs, using differential feature tables.Current thinking on disease management.Step-by-step clinical decision-making, illustrated with patient care algorithms.First reports of serious adverse drug reactions.Clinically useful pharmacodynamics and pharmacokinetics.Developments in pharmacoeconomics and other research that have a bearing on clinical practice.All material is prepared by Adis editors and medical writers, unless otherwise noted. The preparation of material is not supported by any external funding. All review articles are subject to peer review by members of the journal's international editorial board and/or other experts.

Insights into the latest molecular diagnostic and pharmacogenomic techniques and their use in personalized medicine.